Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Danil Stupichev"'
Autor:
Konstantinos N. Blazakis, Danil Stupichev, Maria Kosma, Mohamad Ali Hassan El Chami, Anastasia Apodiakou, George Kostelenos, Panagiotis Kalaitzis
Publikováno v:
Frontiers in Plant Science, Vol 15 (2024)
Traditional morphological analysis is a widely employed tool for the identification and discrimination of olive germplasm by using morphological markers which are monitored by subjective manual measurements that are labor intensive and time-consuming
Externí odkaz:
https://doaj.org/article/df3c1feb4cf94e45b054505562a9bbbf
Autor:
Funda Meric-Bernstam, Nathan Fowler, Ekaterina Postovalova, Zhongmin Xiang, Krystle Nomie, Vladimir Kushnarev, Alexander Bagaev, Danil Stupichev, Kirill Kryukov, Suren Davitavyan, Monique Johnson, Basavaraja Uddajjara Shanthappa
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/785b317c69ae482fa8179679339d17f1
Autor:
Akshaya Ramachandran, Ekaterina Postovalova, Maria Sorokina, Yang Lyu, Jessica H. Brown, James J. Hsieh, Danil Stupichev, Natalia Miheecheva, Krystle Nomie, Alexander Bagaev, Maria Tsiper
Publikováno v:
Clinical Genitourinary Cancer. 19:e374-e381
Although there are immune checkpoint inhibitors (ICIs) available for the treatment of renal cell carcinoma (RCC), the utility of PD-L1 detection by immunohistochemistry (IHC) as a predictive biomarker in clear cell RCC (ccRCC) remains controversial.
Autor:
Yang Lyu, Alexander Bagaev, Krystle Nomie, Ataullakhanov Ravshan I, Nathan Fowler, Ekaterina Postovalova, James J. Hsieh, Natalia Miheecheva, Felix Frenkel, Danil Stupichev, Akshaya Ramachandran
Publikováno v:
Clinical Research (Excluding Clinical Trials).
Autor:
Maria Tsiper, James J. Hsieh, Natalia Miheecheva, Felix Frenkel, Alexander Bagaev, Maria Sorokina, Ekaterina Postovalova, Ataullakhanov Ravshan I, Danil Stupichev, Nathan Fowler, Akshaya Ramachandran, Krystle Nomie, Yang Lyu
Publikováno v:
Cancer Research. 81:161-161
The emergence of immune checkpoint inhibitors (ICI) have revolutionized treatment of many cancer types, including renal cell carcinoma (RCC). Although there are currently three ICI combination regimens approved as standard of care for the first-line